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After a delay of almost two decades, desferrioxamine (DF) has been reintroduced
for clinical use by the pioneering work of British investigators such as Michael
Berry, Bernadette Modell, Martin Pippard and Victor Hoffbrand (1). The
widespread use of DF was firmly established thanks to the exceptional devotion
of our Italian colleagues. In the following, I shall focus on the impact of iron
chelating treatment on survival in Thalassemia; examine the mechanism whereby DF
protects the heart from iron toxicity, and: examine the potential usefulness of
iron chelators in conditions unrelated to iron overload.
(I) Management of transfusional iron overload: Survival in thalassemic patients
in recent years is definitely better than in the pre-DF era. The most extensive
and detailed information on survival in thalassemia comes from Italy, where over
5000 patients with thalassemia major are treated and monitored by a remarkably
well coordinated national study group of the National Association for Pediatric
Oncology and Hematology (AIEOP). In Italy continuous subcutaneous DF treatment
has been introduced and used systematically since 1978 (2). In a report by
Borgna-Pignatti et al (3) on 942 thalassemic patients from Italy, a steady
improvement in survival has been shown for cohorts born in 1960-1964, 1965-1969
and 1970-1974. The total mortality was 15.7% and heart disease was the cause of
death in 2/3. of cases. Overall survival from birth for patients born in
1970-1974 and therefore subjected to chelation therapy from an early age, was
97% at 10 years and 94% at 15 years. These impressive figures illustrate the
significant improvement that has taken place in recent years in the survival of
patients with thalassemia major receiving adequate therapy.
(II) Effect of i.ron.....t.oxicity..and ...chelation on cultured .heart. cells: Because the
most important target of iron toxicity is the heart, we have developed an
experimental model of rat heart cell cultures in which the harmful effects of
iron overload and the beneficial effects of iron chelating treatment may be
studied with complete control of the extracellular environment (4). A unique
feature of this model is the ability to correlate functional abnormalities in
heart cell contractility and rhythmicity induced by iron toxicity, with
structural aberrations such as alterations in membrane lipid and protein
composition. Our studies in cultured heart cells have shown that 24-hour
incubation with iron at concentrations ranging from 20 to 80 micrograms per ml
resulted in a drastic decrease in the amplitude and rate of contractions, a
dose-related decrease in the magnitude of the calcium-dependent overshoot
potential, and gross abnormalities in rhythmicity resembling ventricular
fibrillation in 20 to 30 % of culture plates (5). All of these abnormalities
were abolished by subsequent treatment with DF at a concentration of 0.3 mM.
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Despite enhanced lipid peroxidation indicated by increased malondialdehyde
production (6), alterations in sarcolemmal lipid composition were negligible. In
contrast, there was a marked ecr.ase in the activity of the thiolic sarcolemmal
enzymes 5’-nucleotidase and Na K -ATPase, reversed completely by DF treatment.
Conversely, iron-loading resulted in a sharp increase in the total activity,
increased free activity and loss of latent activity of the lysosomal enzyme
13-hexosaminidase, implying increased lysosomal fragility (7). These observations
indicate that, in addition to increased lysosomal fragility, damage to
sarcolemmal thioli ezymes is an important primary effect of myocardial iron
toxi. Since Na-K--ATPase is directly involved in membrane ion transport and
Ca regulation, damage to thiolic sarcolemmal enzymes may be responsible for
the abnormalities in myocardial function associated with iron overload.
(III) Reperfusion injury" When vital organs are subjected to hypoxia and then
exposed to oxygen during reperfusion, harmful oxygen species are formed which
may aggravate the damage caused by anoxia. This additional damage is referred to
as "reperfusion injury". Superoxide and peroxide are poorly reactive in aqueous
solution, but the hydroxyl radical is a highly reactive, toxic species. Hydroxyl
radicals are produced through the Haber-Weiss reaction which is catalyzed by
iron. Conversely, DF is very efficient in preventing the participation of iron
in the Haber-Weiss reaction and therefore may prevent reperfusion injury.
Prevention of reperfusion injury may have important implications to
post-ischemic damage to the brain or heart, and to the preservation of organs
for transplantation (8,9).
Because of the importance of introducing the chelator prior to reperfusion
damage, the most promising situations in clinical medicine where DF may be
useful are elective surgical procedures and organ transplantation wherein DF
treatment may be started before and throughout cardioplegia and hypothermic
anoxia.
(IV) Cell proliferation: The proliferation of mammalian cells is inhibited by
severe iron deficiency. A similar inhibition of DNA synthesis may be achieved by
in vitro DF treatment of human lymphocytes (10). The mechanism of this
inhibition by DF is interaction with ribonucleotide reductase, a
rate-controlling enzyme in DNA synthesis. This enzyme contains a tyrosine
free-radical structure which is essential for its activity, and which requires
the presence of iron and oxygen The binding of chelatable iron by DF results
in the inactivation of ribonucleotide reductase, similar to the effect of
hydroxyurea, a known inhibitor of this enzyme Important potential applications
of iron chelators in this respect are inhibition of tumour cell growth such as
in neuroblastoma and other malignancies (11), and inhibition of parasite growth
in malaria (12,13) and other parasitic infections.
(V) Drug toxicity" Iron plays an important role in the formation of oxygen
radicals by anthracyclines. Daunorubicin or doxorubicin are reduced to a
semiquinone free radical which, in turn, reduces molecular oxygen to the
superoxide ion. In studies performed recently in our laboratory, (14) we wished
to test the hypothesis that iron may have a role in anthracycline cardiotoxicity
and, conversely, that such toxicity may be inhibited by iron chelators. These
studies have shown that iron-loading prior to doxorubicin treatment causes a 2
to 3-fold increase in doxorubicin toxicity manifested in LDH release, a sharp
decrease in spontaneous heart cell beating, and the emergence of irregular and
84C. Hershko, G. Link, M. Tzahor andA. Pinson Metal-BasedDntgs
ineffective heart cell beats. DF treatment of iron-loaded cells prior to
doxorubicin therapy resulted in decreased doxorubicin toxicity as manifested in
all of the above abnormalities. These observations provide strong support for
the claim that iron- loading may aggravate and iron chelating treatment may
limit the cardiotoxicity of anthracycline drugs.
Conclusions" There can be no doubt today that DF has changed the quality of life
and life expectancy of many patients with thalassemia. The important new
observations on the modification of disease by preventing the formation of free
radicals, and the demonstration of the antiproliferative and antimicrobial
effects of iron chelators lend new meaning to the term "Nutritional Immunity"
and open new channels for exploring the possibility of controlling disease by
selective intracellular iron deprivation. Packaging the chelators in liposomes
or red cell ghosts, or manipulating their lipid solubility to improve their
delivery to appropriate target organs such as the macrophage system may greatly
improve their efficiency. In view of the short half-life of DF and its poor oral
effectiveness it is unlikely that DF per se will be suitable for clinical use as
a practical antimicrobial or antiproliferative agent. However, with the
introduction of simple, orally effective new chelators, it is reasonable to
expect that future research may lead to the identification of iron chelators
with considerable usefulness in the control of a wide range of clinical
problems.
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